What is the 13F Pro Quality Score for VCEL?

13F Pro ranks Vericel Corp (VCEL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VCEL's current score at https://13fpro.ai/research/VCEL (free sign-up required for the full ranking).

Which hedge funds own the most VCEL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of VCEL include BlackRock,, STATE STREET, Soleus Capital Management, L.P.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/VCEL as soon as new 13F filings post.

Where does 13F Pro source VCEL data?

All Vericel Corp fundamentals and ownership data come directly from SEC EDGAR. Vericel Corp files with the SEC under CIK 887359. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VCEL in?

Vericel Corp (VCEL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VCEL research updated on 13F Pro?

VCEL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Vericel Corp(VCEL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 887359 VCEL stock profile & AI dashboard →

13F Pro Quality Score

46.0/100

Rank #1,692 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

78.0/100

Profitability

29.3/100

Balance Sheet

28.0/100

Earnings Quality

30.0/100

Free Cash Flow

65.1/100

Institutional Flow

86.8/100

Revenue Scale

27.1/100

Dilution Risk

13.0/100

VCEL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Vericel Corp (VCEL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VCEL at 46.0/100 on a 32-signal composite quality model, placing it at rank #1,692 of 2,879 stocks — the bottom half of the AI-ranked universe. VCEL scores in the top quartile across institutional flow (86.8), revenue growth (78.0). Areas of concern include revenue scale (27.1) and balance sheet strength (28.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 13.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Vericel Corp reports quarterly revenue of $68.4M, net income of $-6.3M, free cash flow of $15.1M. Top institutional holders of VCEL by reported 13-F value include BlackRock,, STATE STREET, Soleus Capital Management, L.P., based on the most recent SEC filings. VCEL trades on the Nasdaq exchange and files with the SEC under CIK 887359. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VCEL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vericel Corp directly from SEC EDGAR. Vericel Corp's 13F Pro composite quality score has ranged between 8 and 76 since 2021, currently 46.0 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Vericel Corp

Quirks, history, and lore behind VCEL — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in Michigan.
2
The Numbers
Annual revenue in the low hundreds of millions — modest in size, but growing fast in a niche where the addressable patient population is measured in thousands, not millions.
3
The History
Built around cell therapy technologies originally developed in academic and clinical settings, the company commercialized treatments that had been in development for decades before reaching patients.
4
The Secret
Its products aren't pills or devices — they are living cells grown outside the body and implanted back in, making manufacturing more like farming than factory work.
5
The Lore
One of its flagship products, MACI, repairs damaged knee cartilage using a patient's own cells seeded onto a collagen membrane — a favorite among injured athletes who'd rather not have a metal knee at 35.
6
The Giveaway
Its other key product, Epicel, grows permanent skin grafts from a postage-stamp-sized biopsy to cover catastrophic burn wounds — a literal life-saving cell culture business.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$68.4M

Net Income

Q1 2026

$-6.3M

Free Cash Flow

Q1 2026

$15.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+16.5% YoY

$276.3MFY 2025

FY22 $164.4MFY23 $197.5MFY24 $237.2MFY25 $276.3M

Net Income

+59.4% YoY

$16.5MFY 2025

FY22 $-16.7MFY23 $-3.2MFY24 $10.4MFY25 $16.5M

Operating Income

+144.4% YoY

$11.0MFY 2025

FY22 $-17.1MFY23 $-6.5MFY24 $4.5MFY25 $11.0M

EPS (Diluted)

+60.0% YoY

$0.32FY 2025

FY22 $-0.35FY23 $-0.07FY24 $0.20FY25 $0.32

Total Assets

+12.8% YoY

$488.0MFY 2025

FY22 $273.0MFY23 $353.7MFY24 $432.7MFY25 $488.0M

Op. Cash Flow

-10.8% YoY

$51.9MFY 2025

FY22 $17.7MFY23 $35.3MFY24 $58.2MFY25 $51.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$276.3M +16.5%	$237.2M +20.1%	$197.5M +20.2%	$164.4M +32.4%	$124.2M +5.4%	$117.8M
Net Income	$16.5M +59.4%	$10.4M +425.6%	$-3.2M +81.0%	$-16.7M -683.4%	$2.9M +129.6%	$-9.7M
Operating Income	$11.0M +144.4%	$4.5M +169.9%	$-6.5M +62.1%	$-17.1M -819.1%	$2.4M +121.1%	$-11.3M
EPS (Diluted)	$0.32 +60.0%	$0.20 +385.7%	$-0.07 +80.0%	$-0.35 -683.3%	$0.06 +127.3%	$-0.22
Total Assets	$488.0M +12.8%	$432.7M +22.4%	$353.7M +29.5%	$273.0M +32.8%	$205.6M +34.2%	$153.2M
Operating Cash Flow	$51.9M -10.8%	$58.2M +64.7%	$35.3M +99.6%	$17.7M +0.7%	$17.6M +344.6%	$-7.2M

AI Insight: VCEL Ratio Trends

VCEL shows strong seasonal profitability pattern but Q1 2026 operating margin of -11.8% signals the recurring first-quarter drag persists.

• Q4 profitability is consistently strong: Q4 2024 OpMargin hit 24.5% and Q4 2025 reached 24.1%, nearly identical peaks.

• TTM OpMargin of 5.4% and TTM NPM of 7.3% confirm the business is profitable on a trailing basis despite quarterly swings.

• Q1 OpMargin swung from -24.3% in Q1 2025 to -11.8% in Q1 2026, a meaningful year-over-year improvement in the seasonally weakest quarter.

• D/E ratio is unavailable across all periods, limiting leverage and balance sheet assessment.

⚠ Deep Q1 losses (-11.8% OpMargin in Q1 2026) recur annually; execution risk rises if Q4 seasonal tailwinds weaken.

⚠ ROIC of -9.0% in Q1 2026 versus 25.3% in Q4 2025 highlights extreme intra-year capital return volatility worth monitoring.

Get alerted when VCEL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Vericel Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VCEL

BlackRock, Inc.
$249.8M7,765,344 sh
STATE STREET CORP
$101.4M3,152,130 sh
Soleus Capital Management, L.P.
$82.0M2,549,079 sh
Conestoga Capital Advisors, LLC
$79.2M2,463,312 sh
VANGUARD CAPITAL MANAGEMENT LLC
$71.8M2,230,756 sh
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
$59.0M1,832,709 sh
BNP Paribas Asset Management Holding S.A.
$55.4M1,723,572 sh
GENEVA CAPITAL MANAGEMENT LLC
$53.0M1,646,818 sh
CONGRESS ASSET MANAGEMENT CO /MA
$48.5M1,506,918 sh
GEODE CAPITAL MANAGEMENT, LLC
$40.4M1,254,862 sh

Fund	Value	Shares
BlackRock, Inc.	$249.8M	7,765,344
STATE STREET CORP	$101.4M	3,152,130
Soleus Capital Management, L.P.	$82.0M	2,549,079
Conestoga Capital Advisors, LLC	$79.2M	2,463,312
VANGUARD CAPITAL MANAGEMENT LLC	$71.8M	2,230,756
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	$59.0M	1,832,709
BNP Paribas Asset Management Holding S.A.	$55.4M	1,723,572
GENEVA CAPITAL MANAGEMENT LLC	$53.0M	1,646,818
CONGRESS ASSET MANAGEMENT CO /MA	$48.5M	1,506,918
GEODE CAPITAL MANAGEMENT, LLC	$40.4M	1,254,862

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VCEL on your watchlist

Track score changes the day Vericel Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VCEL a good stock to buy?

13F Pro's AI-powered analysis of Vericel Corp (VCEL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VCEL are available on the VCEL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VCEL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VCEL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Vericel Corp's investment landscape.